

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/868,215	06/14/2001	Monika Junghans	WFG/12544	6039
7609	7590 08/26/2003			
RANKIN, HILL, PORTER & CLARK, LLP 700 HUNTINGTON BUILDING 925 EUCLID AVENUE, SUITE 700			EXAMINER	
			SHEINBERG, MONIKA B	
CLEVELAND, OH 44115-1405			ART UNIT	PAPER NUMBER
			1634	
		·	DATE MAILED: 08/26/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/868,215	JUNGHANS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Monika B Sheinberg	1634				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet w	th the correspondenc address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM						
THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a replace of If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	136(a). In no event, however, may a i bly within the statutory minimum of thin will apply and will expire SIX (6) MON e, cause the application to become Al	eply be timely filed  y (30) days will be considered timely.  ITHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 06	June 2003 .					
2a)⊠ This action is <b>FINAL</b> . 2b)□ Ti	his action is non-final.					
3) Since this application is in condition for allow						
closed in accordance with the practice under <b>Disposition of Claims</b>	Ex parte Quayle, 1935 C.	D. 11, 453 O.G. 213.				
4)⊠ Claim(s) <u>28-33 and 35-53</u> is/are pending in the	ne application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>28-33 and 35-53</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers	or					
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documen	ts have been received.					
2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the price application from the International But See the attached detailed Office action for a list.	ureau (PCT Rule 17.2(a)).	_				
14) Acknowledgment is made of a claim for domest	•					
a) The translation of the foreign language pr 15) Acknowledgment is made of a claim for domes	ovisional application has b	een received.				
Attachment(s)	priority arrast 00 0.0.0.	33				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) nformal Patent Application (PTO-152) tailed Action .				

Application/Control Number: 09/868,215

Art Unit: 1634

#### **DETAILED ACTION**

### Response to Amendment filed 06 June 2003

Applicants' arguments, filed 06 June 2003, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

• Claims 28-33 and 35-53, are rejected under 35 U.S.C. 103(a) as being unpatentable over Wolfert et al. (Gene Therapy, 1996) in view of Hanson et al. (WO 95/25809; 28-Sept-1995), and further in view of Wu et al. (WO 93/04701; 18-March-1993) and Zobel et al. (Antisense Nuc. Acid. Drug Devel., 1997).

This rejection is maintained with respect to claims 28-33, 35-50 for reasons of record and newly applied to claims 51-53. Applicants argue that none of the references applied describe the relative proportions required by claim 38 to make the particle are taught. However the instant

Application/Control Number: 09/868,215

Art Unit: 1634

limitation of adjusting molar ratios of protein to nucleic acid, is not a requirement of claims 28-33, 35, 36, 48-51 and 53. As such the argument does not apply to these claims.

Applicants argue that Wolfert *et al.* does not provide any motivation to combine the indicated references. As per the applicants' interpretation of Wolfert *et al.* of the motivation statement selected by the examiner, the reason for using a polycation such as polylysine was due to the better toxicity tolerance of its lower molecular weight. One of ordinary skill in the art would have motivated to use equivalently low molecular weight polycations such as that of arginine for the same reason of decreasing toxicity as per Wolfert *et al.* 

Applicants further argue that Hanson *et al.* does not demonstrate the production of synthetic particles because the reference prevents the particle precipitation purposely by the addition of chaotropic agents. However, this argument does not apply to the particle itself (claims 28-33, 35, 36 and 51) and the method of using (48-50 and 53); wherein the particle itself whether or not in a salt-free environment, exists as per the requirements of the particle claimed in claims 28-33, 35, 36, 48-51 and 53. In regards to claims 37-47 and 52, Hanson *et al.* performs the process of particle formation in a salt-free environment with a subsequent addition of salt (p. 32, lines 8-20); and allows for the manipulation of the solution in the "judicious use" of chaotropic agents (p. 29, lines 29-32). The use of "comprising" claim language allows for additional steps to occur thus the claims encompass the subsequent addition of salts. It is also noted that the particles formed as per Wolfert *et al.* are demonstrated to be "always formed in water" (p. 272, 2<sup>nd</sup> column, 3<sup>rd</sup> paragraph).

Applicants argue that Zobel *et al.* does not mention the use of arginine. However the reference was not relied on for the use of arginine but for the motivation to alter surface charge to compress the particle to the required size limitations as suggested by Wolfert *et al.* It is also noted that the desired surface charges are attained through the variation of oligonucleotide and particle ratios (bridging paragraph of pp. 484-485) thus rendering the argument non-persuasive of the reference failing to adjust molar ratios of protein to nucleic acid for surface charge.

With respects to the new claims 28, 48, 51 and 53, the use of a protein that comprises more than 50% or 60% arginine is demonstrated by the utilization of protamine (also required by claims 29 and 49) as previously described in the previous action mailed 29 January 2003.

Therefore, the arguments are non-persuasive to overcome the rejection.

Art Unit: 1634

#### Conclusion

• Claims 28-33, 35-53, are rejected under 35 U.S.C. 103(a) as being unpatentable over Wolfert et al. in view of Hanson et al., and further in view of Wu et al. and Zobel et al. —maintained. No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

## Inquiries

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Monika B. Sheinberg, whose telephone number is (703) 306-0511. The examiner can normally be reached on Monday-Friday from 9 A.M to 5 P.M. If attempts to reach the examiner by telephone are unsuccessful, the primary examiner in charge of the prosecution of this case, Jehanne Souaya, can be reached at 703-308-6565. If attempts to reach the examiners are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Patent Analyst, Chantae Dessau, whose telephone number is (703) 605-1237, or to the Technical Center receptionist whose telephone number is (703) 308-0196.

August 25, 2003 Monika B. Sheinberg Art Unit 1634

JEHANNE SOUAYA
PATENT EXAMINER

august 25,2003